BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36121093)

  • 1. Estimation of Human Absorbed Dose of
    Vosoughi S; Salek N; Yousefnia H; Delavari M; Reza Aghamiri SM; Ranjbar H
    Curr Radiopharm; 2023; 16(1):64-70. PubMed ID: 36121093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women.
    Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Pichardo-Romero PA
    Nucl Med Commun; 2008 Aug; 29(8):741-7. PubMed ID: 18753829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
    Ferro-Flores G; Arteaga de Murphy C; Rodriguez-Cortés J; Pedraza-López M; Ramírez-Iglesias MT
    Nucl Med Commun; 2006 Apr; 27(4):371-6. PubMed ID: 16531924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
    Faintuch BL; Teodoro R; Duatti A; Muramoto E; Faintuch S; Smith CJ
    Nucl Med Biol; 2008 May; 35(4):401-11. PubMed ID: 18482677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
    Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
    J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands].
    Hernández-Cairo A; Perera-Pintado A; Prats-Capote A; Batista-Cuellar JF; Casacó-Santana C
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):61-5. PubMed ID: 22305264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
    Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internal dosimetry studies of
    Sahafi-Pour SA; Shirmardi SP; Saeedzadeh E; Baradaran S; Sadeghi M
    Appl Radiat Isot; 2022 Aug; 186():110273. PubMed ID: 35594697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients.
    Zhang J; Li D; Lang L; Zhu Z; Wang L; Wu P; Niu G; Li F; Chen X
    J Nucl Med; 2016 Jan; 57(1):9-14. PubMed ID: 26449838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging.
    Mendoza-Sánchez AN; Ferro-Flores G; Ocampo-García BE; Morales-Avila E; de M Ramírez F; De León-Rodríguez LM; Santos-Cuevas CL; Medina LA; Rojas-Calderón EL; Camacho-López MA
    J Biomed Nanotechnol; 2010 Aug; 6(4):375-84. PubMed ID: 21323111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.